Pieris Pharmaceuticals Announces Successful Completion of Safety Review for 10 mg Dose of Phase 2a Trial of Elarekibep (PRS-060/AZD1402) pittsburghstar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pittsburghstar.com Daily Mail and Mail on Sunday newspapers.
Pieris Pharma (PIRS) Announces Successful Completion of Safety Review for 10 mg Dose of Phase 2a Trial of Elarekibep streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Pieris Pharmaceuticals (NASDAQ:PIRS – Get Rating) is scheduled to announce its earnings results after the market closes on Tuesday, May 9th. Analysts expect the company to announce earnings of ($0.14) per share for the quarter. Pieris Pharmaceuticals Price Performance NASDAQ:PIRS opened at $0.77 on Wednesday. Pieris Pharmaceuticals has a 1-year low of $0.72 and a […]
BOSTON, MA / ACCESSWIRE / May 2, 2023 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology